Over Horizon 2020 Health
With support from Horizon 2020, you will be able to conduct international research projects in support of EU policies for health. With a successful application of the program, companies will receive:
- 1-5M EUR for technology and product development
- IPR - Intellectual Property Rights
- A network of partners for development
- Access to new markets
- Technology and knowledge transfer
The purpose of Horizon 2020 Health is to increase European competitiveness and create new jobs.
Possibilities with Horizon 2020 Health
Horizon 2020 Health offers opportunities for SMEs as well as large companies, regardless of industry and technological level. It offers interesting possibilities for traditional production companies as well as high-tech companies; the key factor is that the company is facing a technological challenge or has a project idea for the solution of a technological/societal challenge. With Horizon 2020 Health, the company can receive co-financing from the EU for project research and development.
The Horizon 2020 Health calls are offered to projects within the following categories (see current calls below):
- Personalised medicine
- Innovative health and care industry
- Infectious diseases and improving global health
- Innovative health and care systems - Integration of care
- Decoding the role of the environment, including climate change, for health and well-being
- Digital transformation in Health and Care
- Trusted digital solutions and Cybersecurity in Health and Care
Requirements for Horizon 2020 Health
There are three primary requirements for a project to be eligible for support from Horizon 2020 Health:
- Level of Innovation - the project/technology must be novel and solve a European health issue.
- Large market potential or socioeconomic impact - min. 100M EUR over 5 years.
- The project demands three partners from three EU countries.
Zie hier de aankomende deadlines voor Horizon 2020 Health. Houd er rekening mee dat u 1-2 maanden nodig heeft voor de voorbereiding van de aanvraag.
Photonic technologies for health applications is a very promising field, where the EU has produced significant results during the past decades; however, industrialization is still lagging behind. The challenges are to develop methods that provide the clinicians with photonics enabled tools to improve or to assess the successes of therapies.
For Innovation Actions the focus in on the following themes: Photonics devices to support monitoring therapeutic progress; Sensor-Based Optimization of Production Processes.
For Research and Innovation Actions the focus in on the following themes: Photonics System on Chip/ System in Package for optical interconnect applications; And photonics systems for advanced imaging to support diagnostics driven therapy.
Regenerative medicine offers hope for untreatable disease and the ageing population, improved quality of life and reduced medical costs. However, so far, regenerative medicine has not yet proved itself in the clinic beyond rare diseases or conditions of limited public health importance. With recent scientific discoveries opening up new approaches to regenerative medicine, the challenge is to use these to extend the regenerative approach to major diseases and conditions.
Projects should focus on innovative translational research to develop regenerative processes towards the ultimate clinical goal of addressing unmet clinical needs of large patient groups.
SC1-BHC-13-2019: Mining big data for early detection of infectious disease threats driven by climate change and other factors
A range of factors is responsible for the (re-)emergence of infectious disease threats, including antimicrobial resistance, altering the epidemiology and spread of disease in a changing global environment. These include drivers such as climate change and associated environmental impacts, population growth, unplanned urbanisation and high mobility, as well as animal husbandry or intensive farming practices.
It is expected that proposals develop: the technology to allow the pooling, access, analysis and sharing of relevant data, including next generation sequencing; the innovative bio-informatics and modelling methodologies that enable risk modelling and mapping; and the analytical tools for early warning, risk assessment and monitoring of (re-)emerging infectious disease threats.
SC1-BHC-28-2019: The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on health
Despite the general acknowledgement by the scientific community that 'Genetics load the gun but environment pulls the trigger' when it comes to the causation of major non-communicable diseases (NCDs), there is persistent uncertainty as to the global burden of disease attributable to environmental (including life-style and climatic) factors, including healthcare costs and negative economic impact. Deciphering the human exposome is a novel way of addressing the challenge to improve health and reduce the overall burden of disease.
Applicants should take advantage of the last decade's rapid technological advances which have opened up new opportunities to collect, combine and analyse large data sets offering new possibilities to understand the contribution of environmental factors to the global health burden of common chronic diseases.
SC1-DTH-01-2019: Big data and Artificial Intelligence for monitoring health status and quality of life after the cancer treatment
Currently available methods and strategies for diagnosis and treatment of cancer help clinicians continuously improve quality of care and prevent cancer deaths in the population. However, often rather aggressive treatment, psychological stress (anxiety and depression) can cause physical and psychological problems that may cause long-term after-cure consequences such as similar or other types of cancer, other types of (chronic) diseases and affect the quality of life of a patient. Therefore, the importance of addressing and, if possible, preventing long-term effects of cancer treatment is growing.
Proposals should focus and deliver on how to better acquire, manage, share, model, process and exploit big data to effectively monitor health status of individual patients, provide overall actionable insights at the point of care and improve quality of life after the cancer treatment.
Across the European Union, medicinal products display differences in names, variations in strength or their package size. The unavailability of a specific product may also necessitate substitution in many instances, if a patient is to be timely served in a pharmacy.
This innovation action is expected to support two goals: (i) the cross-border mobility of European patients by offering safer eDispensations across borders, (ii) the implementation of the IDMP standards in Member States drug databases (including a possible linkage to the EU SPOR - Substance, Product, Organisation and Referential master data database) allowing the identification of locally available medicinal products which are equivalent to the one identified in a foreign prescription.
Senior people are statistically at greater risk of cognitive impairment, frailty and multiple chronic health conditions with consequences for their independence, their quality of life (and the one of their families) but also for the sustainability of health and social care systems. There is also increasing evidence that interactions with the environment play an important role in the evolution of the patient's health status and condition.
The scope of this topic is to foster the large-scale pilots for deployment of trusted and personalised digital solutions dealing with Integrated Care, with a view to supporting and extending healthy and independent living for older individuals who are facing permanently or temporarily reduced functionality and capabilities.
Meld u aan voor de nieuwsservice en blijf op de hoogte omtrent nieuwe aanmeldingen.Aanmelden
Hoor meer betreffende subsidie van Horizon 2020 Health
We nemen graag contact met u op voor een vrijblijvend advies over de Horizon 2020 Health subsidiemogelijkheden voor uw project.
Uw mogelijkheden voor overheidssubsidie
Is overheidssubsidie iets voor uw project? Wij bekijken graag de mogelijkheden.Vertel over uw project
of bel ons (+45) 61 60 75 08